Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1401(HF10) + Ipilimumab in Advanced Melanoma
NCT03153085Phase 2Completed
- Sponsor
- Takara Bio Inc.
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canerpaturev in melanoma, sponsored by Takara Bio Inc. Primary endpoint: Best Overall Response Rate by irRC at 24 weeks. Started May 2017; status: completed.
02
Drugs
canerpaturev
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03153085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153085.